Dr Reddys Laboratories Ltd (DRREDDY)
₹1,151.00
Mkt cap
₹95,256 Cr
P/E ratio
29.60
P/B
2.54
Div yield
0.70%
ROE
11.20%
ROCE
13.00%
EPS (TTM)
₹38.89
Book value
₹454
52W range
1,136–1,376
Sector
Healthcare
Price history
Previous close
Dr. Reddy's Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations.
NSE DRREDDYBSE 500124
Health check
Mixed
ValuationCheap
ProfitabilityAverage
GrowthModerate
TechnicalsBearish
52-week range
−16.33% from high₹1,151
₹1,136+1.36% from low₹1,376
Current
₹1,151.00
Prev close
₹1,144.20
Day
+0.59%
Price performance
1D
+0.59%
1W
−1.71%
1M
−0.67%
3M
−9.49%
6M
−12.37%
1Y
−8.19%
YTD
−8.37%
Financials
Revenue, profit & margin
P/E ratio
29.6×
DRREDDY is 16% below the sector median of 35.2×
DRREDDY29.6×
Sector median35.2×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6,758 | 6,903 | 7,237 | 7,114 | 7,696 | 8,038 | 8,381 | 8,528 | 8,572 | 8,828 | 8,753 | 7,546 | 8,100 | |
| Expenses | 4,696 | 4,894 | 5,214 | 5,283 | 5,566 | 5,962 | 6,108 | 6,530 | 6,398 | 6,818 | 6,866 | 7,164 | 7,240 | |
| Operating Profit | 2,062 | 2,008 | 2,023 | 1,831 | 2,130 | 2,076 | 2,273 | 1,998 | 2,174 | 2,010 | 1,888 | 382 | 860 | |
| OPM % | 31% | 29% | 28% | 26% | 28% | 26% | 27% | 23% | 25% | 23% | 22% | 5% | 11% | |
| Other Income | 178 | 319 | 219 | 201 | 193 | 314 | 154 | 528 | 290 | 330 | 271 | 480 | 356 | |
| Interest | 37 | 35 | 39 | 59 | 60 | 76 | 82 | 66 | 83 | 91 | 94 | 106 | 126 | |
| Depreciation | 353 | 376 | 374 | 368 | 381 | 397 | 471 | 455 | 476 | 505 | 521 | 557 | 537 | |
| Profit before tax | 1,850 | 1,917 | 1,829 | 1,605 | 1,883 | 1,917 | 1,874 | 2,005 | 1,905 | 1,745 | 1,543 | 200 | 553 | |
| Tax % | 24% | 23% | 24% | 18% | 26% | 30% | 25% | 21% | 26% | 23% | 23% | -11% | 21% | |
| Net Profit | 1,405 | 1,482 | 1,381 | 1,310 | 1,392 | 1,342 | 1,404 | 1,587 | 1,410 | 1,337 | 1,190 | 221 | 436 | |
| EPS in Rs | 16.87 | 17.77 | 16.56 | 15.70 | 16.69 | 15.05 | 16.94 | 19.09 | 16.99 | 16.14 | 14.50 | 2.65 | 5.32 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.16% · closed higher next day 32 of last 60
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 27 Oct '23◦ | 30 Jan '24◦ | 7 May '24◦ | 27 Jul '24◦ | 5 Nov '24◦ | 24 Jan '25 | 9 May '25◦ | 23 Jul '25◦ | 24 Oct '25◦ | 21 Jan '26◦ | 12 May '26◦ | 22 Jul '26◦ |
| Earnings day | −0.96% | +4.80% | −3.22% | −0.56% | +2.35% | −5.04% | +3.43% | +1.45% | +0.05% | +5.21% | −0.37% | −1.39% |
| +1 day | −0.55% | +2.61% | −6.08% | −1.08% | +1.19% | −7.12% | +4.43% | +2.45% | +0.45% | +6.77% | +2.65% | −2.63% |
| +5 days | −1.10% | +5.80% | −6.11% | −0.97% | −2.14% | −5.59% | +5.46% | +1.84% | −6.82% | +5.26% | +4.09% | −3.21% |
| +15 days | +4.62% | +8.70% | −4.10% | +1.26% | −5.49% | −5.10% | +7.94% | +1.04% | −3.10% | +9.58% | −0.20% | +1.96% |
| +30 days | +3.73% | +7.77% | −4.58% | −3.32% | +5.62% | −12.11% | +14.02% | +0.26% | −2.91% | +11.22% | +6.34% | −2.35% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 8 Per Share | 8.00 | 10 Jul '26 | 10 Jul '26 |
Shareholding
as of Jun 202626.63%Promoter
Promoters26.63%
FIIs20.67%0.47
DIIs31.75%1.03
Public20.76%0.51
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,895.00 | 35.99 | 4,54,674 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,315.00 | 83.00 | 2,47,284 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,914.00 | 83.89 | 1,87,183 | 0.77% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| ZYDUSLIFE | ₹1,156.90 | 23.70 | 1,15,401 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| CIPLA | ₹1,395.00 | 31.49 | 1,12,696 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| LAURUSLABS | ₹1,876.70 | 92.74 | 1,01,400 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,105.00 | 16.16 | 96,209 | 0.86% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| DRREDDY | ₹1,144.20 | 29.56 | 95,256 | 0.70% | 436 | −68.67% | 8,100 | −5.51% | 13.04% |
| Median: 158 Co. | ₹426.15 | 35.23 | 2,303 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013nseAnnual Report 2013bse
Concall transcripts48
TranscriptJul 2026PPTJul 2026RECJul 2026TranscriptJul 2026RECJul 2026TranscriptMay 2026PPTMay 2026PPTMay 2026TranscriptJan 2026PPTJan 2026RECJan 2026TranscriptOct 2025PPTOct 2025RECOct 2025TranscriptJul 2025PPTJul 2025RECJul 2025TranscriptMay 2025RECMay 2025TranscriptJan 2025RECJan 2025TranscriptNov 2024RECNov 2024TranscriptAug 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 26 AugAnnouncement under Regulation 30 (LODR)-Newspaper Publication 20 AugDisclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 14 Aug - USFDA completed GMP inspection at Bachupally FTO-3; Form 483 issued with four observations.Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 14 Aug - USFDA closed Mirfield API facility inspection as VAI on August 14, 2026.Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 14 Aug